“I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia. “He is an incredibly accomplished executive whose depth of biotech experience, proven leadership and scientific expertise will be invaluable to me and the Board of Directors as we focus on delivering on the Company’s strategy and further advancing the Phase III program for dexpramipexole, the first potential oral drug for eosinophilic asthma.”
AreteiaTx
Biotechnology Research
Research Triangle Park, North Carolina 1,361 followers
Pioneering a new era in asthma control
About us
Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
- Website
-
www.areteiatx.com
External link for AreteiaTx
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Research Triangle Park, North Carolina
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
Research Triangle Park, North Carolina, US
-
Get directions
Short Hills, New Jersey, US
Employees at AreteiaTx
Updates
-
Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma - We are proud to announce that this will support significant expansion of the existing program, including adding clinical development in Japan along with several additional global markets, expansion of manufacturing activities and additional life-cycle management including development of a once-daily formulation. Viking Global Investors and Marshall Wace to join the syndicate. More information here: https://lnkd.in/eUBs-de8
Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
businesswire.com
-
We are pleased to announce that results from the phase II EXHALE-1 study of oral dexpramipexole in eosinophilic asthma have been published online in the Journal of Allergy and Clinical Immunology.
Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma
businesswire.com